Alkermes plc. — Form 8-K
Filed September 21, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 52/100
What the filing says
Alkermes announced positive Phase 1b results for ALKS 7290, an orexin 2 receptor agonist, in 50 adults with ADHD. The drug demonstrated clinically meaningful dose-dependent improvements on AISRS (14-point reduction at 20 mg, 19-point at 50 mg) and CGI-S scales (1.0 and 2.0-point reductions respectively at day 14), was well tolerated with no serious adverse events, and represents the first clinical evidence of an orexin receptor agonist in ADHD treatment. A Phase 2 study enrolling ~312 participants began dosing in September 2026 with data expected in 2027.
Why this rating
Early-stage pipeline advancement with proof-of-concept achieved; meaningful but exploratory data in small patient cohort ($4.7B company); Phase 2 risk remains high, clinical benefit vs. existing ADHD therapies unproven.
See more from September 21, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.